三元生物
(301206)
| 流通市值：29.43亿 | | | 总市值：55.34亿 |
| 流通股本：1.08亿 | | | 总股本：2.02亿 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 86,800,655.34 | 76,792,909.06 | 101,631,627.34 | 108,808,330.03 |
| 应收票据及应收账款 | 79,531,046.42 | 83,188,224.95 | 99,685,190.73 | 80,928,284.07 |
| 其中：应收票据 | 5,618,307 | 3,431,957 | 2,919,883 | 2,215,370.65 |
| 应收账款 | 73,912,739.42 | 79,756,267.95 | 96,765,307.73 | 78,712,913.42 |
| 预付款项 | 12,474,024.63 | 8,162,224.61 | 9,610,055.72 | 11,070,972.47 |
| 其他应收款合计 | 4,263,214.61 | 4,297,905.75 | 5,590,630.57 | 6,549,400.89 |
| 存货 | 118,786,624.02 | 148,244,242.15 | 125,818,366.87 | 104,331,077.04 |
| 一年内到期的非流动资产 | 2,916,095,465.9 | - | - | - |
| 其他流动资产 | 8,253,136.38 | 14,448,276.1 | 8,684,735.96 | 10,125,789.47 |
| 流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 流动资产合计 | 3,356,204,167.3 | 335,133,782.62 | 351,020,607.19 | 321,813,853.97 |
| 非流动资产: | | | | |
| 长期股权投资 | 58,657,213.74 | 58,710,967.79 | 58,833,405.63 | 58,897,956.66 |
| 固定资产 | 989,234,419.37 | 866,742,308.95 | 866,686,073.02 | 883,575,315.67 |
| 在建工程 | 47,839,909.23 | 154,983,218.34 | 125,235,082.64 | 103,692,334.84 |
| 无形资产 | 46,712,598.83 | 47,000,575.46 | 47,288,552.09 | 47,576,528.72 |
| 其他非流动资产 | 268,077,946.42 | 3,387,723,146.45 | 3,433,216,948.56 | 3,394,870,445.92 |
| 非流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 非流动资产合计 | 1,410,522,087.59 | 4,515,160,216.99 | 4,531,260,061.94 | 4,488,612,581.81 |
| 资产平衡项目 | 0 | 0 | 0 | 0 |
| 资产总计 | 4,766,726,254.89 | 4,850,293,999.61 | 4,882,280,669.13 | 4,810,426,435.78 |
| 流动负债: | | | | |
| 应付票据及应付账款 | 168,724,477.68 | 244,886,712.96 | 252,870,377.58 | 208,572,319.13 |
| 其中：应付票据 | 111,286,205.74 | 192,231,998.44 | 198,858,761 | 162,332,370 |
| 应付账款 | 57,438,271.94 | 52,654,714.52 | 54,011,616.58 | 46,239,949.13 |
| 合同负债 | 5,337,921.22 | 4,289,650.9 | 9,073,731.27 | 5,178,477.21 |
| 应付职工薪酬 | 5,929,062.19 | 5,264,263.54 | 5,031,793.37 | 6,943,645.31 |
| 应交税费 | 2,481,703.14 | 1,122,057.15 | 1,146,328.67 | 1,122,869.53 |
| 其他应付款合计 | 69,488.6 | 85,634 | 275,181 | 75,477 |
| 其他流动负债 | 4,940,330 | 3,622,354.08 | 2,463,132.27 | 2,304,224.84 |
| 流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 流动负债合计 | 187,482,982.83 | 259,270,672.63 | 270,860,544.16 | 224,197,013.02 |
| 非流动负债: | | | | |
| 递延收益 | 3,838,210.8 | 4,089,755.25 | 4,341,299.7 | 4,592,844.15 |
| 递延所得税负债 | 48,350,281.47 | 47,578,733.52 | 44,808,647.48 | 43,614,073.1 |
| 非流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 非流动负债合计 | 52,188,492.27 | 51,668,488.77 | 49,149,947.18 | 48,206,917.25 |
| 负债平衡项目 | 0 | 0 | 0 | 0 |
| 负债合计 | 239,671,475.1 | 310,939,161.4 | 320,010,491.34 | 272,403,930.27 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 202,325,700 | 202,325,700 | 202,325,700 | 202,325,700 |
| 资本公积 | 3,517,613,730.51 | 3,517,613,730.51 | 3,517,613,730.51 | 3,517,613,730.51 |
| 减:库存股 | 11,113,724.66 | - | - | - |
| 盈余公积 | 81,132,379.87 | 78,216,111.43 | 73,020,084.59 | 73,020,084.59 |
| 未分配利润 | 737,096,694.07 | 741,199,296.27 | 769,310,662.69 | 745,062,990.41 |
| 归属于母公司股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 归属于母公司股东权益合计 | 4,527,054,779.79 | 4,539,354,838.21 | 4,562,270,177.79 | 4,538,022,505.51 |
| 股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 股东权益合计 | 4,527,054,779.79 | 4,539,354,838.21 | 4,562,270,177.79 | 4,538,022,505.51 |
| 负债和股东权益合计 | 4,766,726,254.89 | 4,850,293,999.61 | 4,882,280,669.13 | 4,810,426,435.78 |
| 公告日期 | 2024-10-30 | 2024-08-30 | 2024-04-23 | 2024-04-23 |
| 审计意见(境内) | | | | 标准无保留意见 |